ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0139

Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040

CLAUDIA MENDOZA-PINTO1, IVET ETCHEGARAY MORALES2, PAMELA MUNGUIA-REALPOZO1, Socorro Méndez-Martínez3, Álvaro Montiel-Jarquín1, Roberto Berra-Romani4, Fernanda Solis-Mendoza5 and Mario García-Carrasco6, 1Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 3Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, 4Benemérita Universidad Autónoma de PueblaPueblam, Puebla, Puebla, Mexico, 5Universidad de las Américas de Puebla, Puebla, Puebla, Mexico, 6Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico

Meeting: ACR Convergence 2024

Keywords: Demographics, Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder related to disability and premature mortality. Nowadays, the burden of RA is needed for healthcare planning, resource allocation, and prevention. Considering the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we analyze updated estimates of the prevalence of RA and its associated disability-adjusted life-years (DALYs) and mortality by age, sex, year, and location, with forecasted prevalence to 2040.

Methods: We analyzed the incidence, prevalence, mortality, and burden of suffering of RA based on epidemiological data from the Global Burden of Disease (GBD) current dataset from the Institute of Health Metrics, Seattle. National trends from 1990 to 2019 of RA for all ages were compiled. Forecast estimates were obtained using the SPSS Time Series Modeler.

Results: In 2019, approximately 530,000 individuals were affected by RA, corresponding to 0.5% of the Mexican population (64.0% were females, and 35.9% were aged 15–49 years). The age-standardized prevalence and incidence rates were 427.6 cases and 25.4 per 100,000 inhabitants, respectively. In 2019, the Mexican states with the highest age-standardized prevalence, DALY, and YLD rates were Oaxaca, Tlaxcala, and Zacatecas. The national prevalence and incidence rates of RA are projected to increase to 465.5 and 27.9 by 2030 and 518.9 and 30.2 per 100,000 inhabitants, higher in females than males. In contrast, the overall age-standardized mortality and DALY rates are projected to decrease to 1.2 and 77.8 by 2030 and 1.1 and 73.6 by 2040 per 100,000 inhabitants.

Conclusion: RA continues to increase in burden, particularly in disability burden. Despite significant investments in clinical care, research, and public health interventions, there appears to be no sign of a reduction in the rate of increase. Certain regions of Mexico, such as Mexico City, Oaxaca, and Zacatecas, are experiencing a disproportionately high burden.

Supporting image 1

Table. Age-standardized prevalence, incidence, mortality, and DALY per 100,000 persons from RA in 2030 and 2040, overall and by sex.


Disclosures: C. MENDOZA-PINTO: None; I. ETCHEGARAY MORALES: None; P. MUNGUIA-REALPOZO: None; S. Méndez-Martínez: None; Á. Montiel-Jarquín: None; R. Berra-Romani: None; F. Solis-Mendoza: None; M. García-Carrasco: None.

To cite this abstract in AMA style:

MENDOZA-PINTO C, ETCHEGARAY MORALES I, MUNGUIA-REALPOZO P, Méndez-Martínez S, Montiel-Jarquín Á, Berra-Romani R, Solis-Mendoza F, García-Carrasco M. Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040 [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/analysis-of-rheumatoid-arthritis-epidemiology-in-mexico-using-the-gbd-2019-study-and-forecasting-future-trends-for-2030-and-2040/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-rheumatoid-arthritis-epidemiology-in-mexico-using-the-gbd-2019-study-and-forecasting-future-trends-for-2030-and-2040/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology